Santhera Pharmaceuticals Holding AG Stock price

Equities

SANN

CH1276028821

Pharmaceuticals

Real-time Estimate Cboe Europe 08:00:27 2024-03-28 am EDT 5-day change 1st Jan Change
9.655 CHF -0.16% Intraday chart for Santhera Pharmaceuticals Holding AG +1.89% -1.33%
Sales 2023 * 8.29M 9.15M Sales 2024 * 51.09M 56.42M Capitalization 89.08M 98.37M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 10.7 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.74 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 46
Yield 2023 *
-
Yield 2024 *
-
Free-Float 70.73%
More Fundamentals * Assessed data
Dynamic Chart
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China MT
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment MT
Swiss Equities Edge Down After Central Banks Buzz MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers MT
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer CI
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy CI
Santhera, Catalyst Pharmaceuticals Secure US FDA Nod for Rare Neuromuscular Disease Drug MT
Catalyst Pharmaceuticals Says Santhera's Agamree Gains FDA Approval for Duchenne Muscular Dystrophy Treatment MT
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval DJ
US FDA approves Santhera's drug for rare muscular dystrophy RE
More news

Latest transcript on Santhera Pharmaceuticals Holding AG

1 day-0.16%
1 week+1.89%
Current month-6.92%
1 month-11.68%
3 months-2.62%
6 months+19.95%
Current year-1.33%
More quotes
1 week
9.21
Extreme 9.21
9.84
1 month
9.01
Extreme 9.01
11.00
Current year
8.83
Extreme 8.83
11.44
1 year
6.01
Extreme 6.01
14.62
3 years
5.00
Extreme 5
34.90
5 years
5.00
Extreme 5
179.60
10 years
5.00
Extreme 5
1 389.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-11-30
Founder 62 04-09-06
Director of Finance/CFO 61 20-03-31
Members of the board TitleAgeSince
Founder 62 04-09-06
Director/Board Member 56 17-04-03
Director/Board Member 68 23-06-26
More insiders
Date Price Change Volume
24-03-28 9.68 +0.10% 5 591
24-03-27 9.67 -1.12% 20,901
24-03-26 9.78 +0.82% 50,502
24-03-25 9.7 +1.04% 30,774
24-03-22 9.6 +1.05% 11,600

Delayed Quote Swiss Exchange, March 28, 2024 at 08:00 am EDT

More quotes
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.67 CHF
Average target price
30 CHF
Spread / Average Target
+210.24%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Santhera Pharmaceuticals Holding AG - Swiss Exchange